Hospital
Monongahela Valley Hospital, INC.
Monongahela Valley Hospital, INC. was paid $3.93M by Medicaid between Dec 2019 and Sep 2023, across 185 billing codes. Its largest line is G0378, Hospital observation service, per hour — 27% of everything it billed.
33Billing provider infoMONONGAHELA VALLEY HOSPITAL, INC.
MONONGAHELA, PA 15063
MONONGAHELA, PA 15063
33aNPI1639353428assigned 12/28/2007
33bProvider typeSubstance Use Disorder Rehabilitation Hospital Unit
28Total paid$3.93M
24GClaims135,639
24DCodes billed185
24AFirst – last monthDec 2019 – Sep 2023
Compared with peers
Next to other Substance Use Disorder Rehabilitation Hospital Unit providers in Pennsylvania
Rank by total paid#3 of 6
Median peer was paid$744K
This provider vs. median5.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official STRISHOCK, JOURDAN controls 16+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 161 | $791.17 | |
| 2020 | 12,987 | $348K | |
| 2021 | 80,385 | $2.49M | |
| 2022 | 22,390 | $583K | |
| 2023 | 19,716 | $507K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0378 | Hospital observation service, per hour | 27% | 792 | 747 | $1.07M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 6,456 | 6,294 | $723K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.8% | 4,439 | 4,351 | $347K |
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 7.6% | 5,461 | 1,811 | $297K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.4% | 1,802 | 1,744 | $174K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.1% | 617 | 592 | $84K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.9% | 815 | 805 | $76K |
| 80053 | Comprehensive metabolic panel | 1.8% | 7,753 | 6,928 | $71K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.4% | 2,304 | 2,223 | $57K |
| 80050 | General health panel | 1.2% | 1,190 | 1,170 | $49K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 11,032 | 9,077 | $48K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.0% | 280 | 277 | $41K |
173 more codes
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.0% | 5,383 | $41K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 710 | $36K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,068 | $36K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 402 | $32K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 201 | $30K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 322 | $28K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 733 | $24K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 367 | $23K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,566 | $21K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 514 | $20K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 526 | $19K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 719 | $19K |
| 84484 | <1% | 2,781 | $19K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 720 | $19K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,644 | $18K |
| 80061 | Lipid panel | <1% | 1,313 | $17K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 847 | $17K |
| 83735 | <1% | 3,521 | $16K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 74 | $15K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 53 | $15K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 216 | $15K |
| 85730 | <1% | 2,848 | $14K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 352 | $12K |
| 87481 | <1% | 166 | $12K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 152 | $12K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,408 | $12K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 589 | $11K |
| 81001 | <1% | 4,507 | $11K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 123 | $11K |
| 87625 | <1% | 265 | $11K | |
| 85610 | <1% | 3,869 | $10K | |
| 84703 | <1% | 1,005 | $10K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 828 | $10K |
| 93975 | <1% | 87 | $9K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 402 | $9K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 224 | $8K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,007 | $8K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 177 | $8K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 322 | $8K |
| 76830 | Ultrasound, transvaginal | <1% | 168 | $7K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 182 | $7K |
| 88342 | <1% | 150 | $7K | |
| 87480 | <1% | 222 | $6K | |
| 87660 | <1% | 222 | $6K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 179 | $5K |
| 73564 | <1% | 240 | $5K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 411 | $5K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 786 | $5K |
| 71250 | <1% | 99 | $5K | |
| 72131 | <1% | 76 | $5K | |
| 83690 | <1% | 1,259 | $5K | |
| 83880 | <1% | 277 | $5K | |
| 76641 | <1% | 70 | $5K | |
| 85378 | <1% | 680 | $4K | |
| 82607 | <1% | 399 | $4K | |
| 0001A | <1% | 88 | $4K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 822 | $4K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 37 | $4K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 778 | $4K |
| 83605 | <1% | 785 | $4K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 87 | $4K |
| 93971 | <1% | 66 | $4K | |
| 0002A | <1% | 83 | $4K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 450 | $4K |
| 73610 | <1% | 217 | $4K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 90 | $4K |
| 96367 | <1% | 337 | $3K | |
| 87040 | <1% | 462 | $3K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 546 | $3K |
| 80076 | <1% | 433 | $3K | |
| 84702 | <1% | 169 | $3K | |
| 73630 | <1% | 270 | $3K | |
| 93017 | <1% | 173 | $3K | |
| J3490 | Unclassified drugs | <1% | 698 | $3K |
| 84439 | <1% | 350 | $3K | |
| 76536 | <1% | 59 | $3K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 14 | $3K |
| 93970 | <1% | 42 | $3K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 39 | $3K |
| 0004A | <1% | 47 | $2K | |
| 87077 | <1% | 422 | $2K | |
| 82728 | <1% | 222 | $2K | |
| 84153 | <1% | 99 | $2K | |
| 87070 | <1% | 368 | $2K | |
| 82150 | <1% | 571 | $2K | |
| 83540 | <1% | 276 | $2K | |
| 72141 | <1% | 13 | $2K | |
| 86803 | <1% | 94 | $2K | |
| 77066 | Tomosynthesis, mammo | <1% | 28 | $2K |
| 73030 | <1% | 118 | $2K | |
| 81025 | <1% | 608 | $2K | |
| 87186 | <1% | 304 | $2K | |
| 84436 | <1% | 187 | $2K | |
| 82550 | <1% | 426 | $2K | |
| 82043 | <1% | 196 | $1K | |
| 80074 | <1% | 32 | $1K | |
| 86850 | <1% | 335 | $1K | |
| 82570 | <1% | 202 | $1K | |
| 84100 | <1% | 316 | $1K | |
| 82746 | <1% | 146 | $1K | |
| 83550 | <1% | 243 | $1K | |
| 94729 | <1% | 41 | $1K | |
| 73130 | <1% | 88 | $1K | |
| 72110 | <1% | 47 | $909.81 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 133 | $898.98 |
| 73502 | <1% | 40 | $897.13 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 76 | $813.39 |
| J1815 | Injection, insulin, per 5 units | <1% | 120 | $765.60 |
| 86900 | <1% | 338 | $759.08 | |
| 70486 | <1% | 12 | $758.39 | |
| 86038 | <1% | 54 | $753.58 | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 12 | $750.61 |
| 87275 | <1% | 66 | $746.50 | |
| 86140 | <1% | 302 | $736.00 | |
| 85651 | <1% | 284 | $713.53 | |
| 87205 | <1% | 172 | $695.31 | |
| 86901 | <1% | 338 | $646.04 | |
| 94727 | <1% | 40 | $645.12 | |
| 90715 | <1% | 38 | $558.20 | |
| 82565 | <1% | 100 | $524.76 | |
| 81514 | <1% | 59 | $520.00 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,875 | $519.59 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,097 | $505.73 |
| 83970 | <1% | 14 | $488.72 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 527 | $422.45 |
| 97161 | <1% | 96 | $389.75 | |
| J3535 | Drug administered through a metered dose inhaler | <1% | 30 | $336.00 |
| 94060 | <1% | 40 | $335.28 | |
| 88312 | <1% | 13 | $317.55 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 12,550 | $286.85 |
| 11043 | <1% | 15 | $285.77 | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 14 | $278.40 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 113 | $255.18 |
| 88313 | <1% | 14 | $252.45 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 393 | $252.35 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 708 | $250.65 |
| 77062 | <1% | 14 | $250.01 | |
| 86592 | <1% | 54 | $248.44 | |
| 82378 | <1% | 17 | $244.13 | |
| 97165 | <1% | 13 | $226.95 | |
| 82553 | <1% | 102 | $207.84 | |
| J2704 | Injection, propofol, 10 mg | <1% | 511 | $175.78 |
| 87510 | <1% | 222 | $157.20 | |
| 73110 | <1% | 14 | $152.40 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,875 | $140.57 |
| 87081 | <1% | 784 | $113.49 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 124 | $108.88 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 517 | $96.25 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 329 | $47.36 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 87 | $46.94 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 735 | $44.06 |
| A4657 | Syringe, with or without needle, each | <1% | 1,096 | $32.85 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 42 | $28.90 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 18 | $26.64 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 18 | $24.80 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 113 | $17.60 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 275 | $15.17 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 364 | $15.04 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 46 | $12.90 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 87 | $11.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 356 | $10.13 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 379 | $7.79 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 56 | $7.70 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 199 | $7.10 |
| E0114 | Crutches underarm, other than wood, adjustable or fixed, pair, with pads, tips and handgrips | 0% | 64 | $0.00 |
| A4550 | Surgical trays | 0% | 143 | $0.00 |
| A6210 | Foam dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing | 0% | 21 | $0.00 |
| A4628 | Oral and/or oropharyngeal suction catheter, each | 0% | 44 | $0.00 |
| A4615 | Cannula, nasal | 0% | 180 | $0.00 |
| 36591 | 0% | 66 | $0.00 | |
| 87276 | 0% | 66 | $0.00 | |
| 87280 | 0% | 17 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSTRISHOCK, JOURDAN (COMPLIANCE SUPERVISOR)
Parent organizationPENN HIGHLANDS HEALTHCARE
| Provider | Location | Paid |
|---|---|---|
| Highlands Hospital and Health Center | Connellsville, PA | $4.47M |
| Monongahela Valley Hospital, INC. | Monongahela, PA | $3.58M |
| Dubois Regional Medical Center | Clearfield, PA | $1.79M |
| Tyrone Hospital | Tyrone, PA | $1.44M |
| Penn Highlands Home Medical Equipment LLC | Clearfield, PA | $177K |
| Penn Highlands Home Medical Equipment LLC | Saint Marys, PA | $134K |
| Penn Highlands Home Medical Equipment LLC | Du Bois, PA | $29K |
| Highlands Hospital and Health Center | Connellsville, PA | $16K |
| Dubois Regional Medical Center | Du Bois, PA | $10K |
| J C Blair Memorial Hospital | State College, PA | $7K |
| Monongahela Valley Hospital, INC. | Monongahela, PA | $4K |
| JC Blair Memorial Hospital | Huntingdon, PA | $2K |
| Monongahela Valley Hospital, INC. | Monongahela, PA | $404.23 |
| J. C. Blair Memorial Hospital | Huntingdon, PA | $346.50 |
| Monongahela Valley Hospital, INC | Uniontown, PA | $320.93 |
| Mon-Vale Oncology, INC. | Monongahela, PA | $309.50 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.